Aquestive Therapeutics Inc (OQ:AQST)
Business Focus: Pharmaceuticals
| Sector: Healthcare | Industry: Pharmaceuticals |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 30 Technology Dr WARREN NJ 07059-5166 |
| Tel: | N/A |
| Website: | https://aquestive.com |
| IR: | See website |
| Key People | ||
| Daniel Barber President, Chief Executive Officer, Director | A. Ernest Toth Chief Financial Officer, Senior Vice President | Lori J. Braender Chief Compliance Officer, Senior Vice President, General Counsel and Corporate Secretary |
| Peter E. Boyd Senior Vice President - Information Technology, Human Resources and Communications | Cassie Jung Senior Vice President - Operations | Kenneth W. Marshall Senior Vice President, Chief Commercial Officer |
| Stephen Wargacki Senior Vice President - Research and Development | A. Mark Schobel Chief Innovation and Technology Officer | Carl Kraus Chief Medical Officer |
| Business Overview |
| Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies. It is advancing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis. It has also developed a product pipeline focused on treating diseases of the central nervous system (CNS). Its PharmFilm technology is comprised of proprietary polymer compositions that serve as film formers to hold active pharmaceutical ingredients (APIs), and excipients in place. Its product portfolio and pipeline include Anaphylm, AQST-108, and Adrenaverse. Its CNS product candidate include Libervant. The Company's Licensed commercial products and product candidates and other product includes Suboxone, Exservan, KYNMOBI, Zuplenz, Azstarys, Libervant, and Sympazan. Anaphylm is a non-device based, orally delivered epinephrine product candidate. |
| Financial Overview |
| For the fiscal year ended 31 December 2023, Aquestive Therapeutics Inc revenues increased 6% to $50.6M. Net loss decreased 86% to $7.9M. Revenues reflect Ex-United States segment increase of 74% to $13.5M. Lower net loss reflects Selling, General and administrative decrease of 40% to $29.7M (expense), Interest income and other income, net increase from $99K to $16.3M (income). |
| Employees: | 135 as of Dec 31, 2023 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $337.64M as of Dec 31, 2023 |
| Annual revenue (TTM): | $50.58M as of Dec 31, 2023 |
| EBITDA (TTM): | -$13.80M as of Dec 31, 2023 |
| Net annual income (TTM): | -$7.87M as of Dec 31, 2023 |
| Free cash flow (TTM): | -$7.38M as of Dec 31, 2023 |
| Net Debt Last Fiscal Year: | $3.66M as of Dec 31, 2023 |
| Shares outstanding: | 85,199,752 as of Mar 19, 2024 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.